Abstract 3737: BXQ-350: A novel biologic that targets dysregulated sphingolipid metabolism and normalizes key anti-tumoral and pro-tumoral sphingolipids in newly diagnosed metastatic colorectal carcinoma patients (mCRC)
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: Bexion Pharmaceuticals (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7148645888
Cites:
Cited by:
Related to: